Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
1,340,581
-
Shares change
-
-1,696,445
-
Total reported value, excl. options
-
$2,396,972
-
Value change
-
-$2,122,564
-
Number of buys
-
6
-
Number of sells
-
-14
-
Price
-
$1.78
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q3 2024
29 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q3 2024.
Gain Therapeutics, Inc. - COM (GANX) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,340,581 shares
.
Largest 10 shareholders include DME Capital Management, LP (566,130 shares), GEODE CAPITAL MANAGEMENT, LLC (271,972 shares), VANGUARD GROUP INC (145,217 shares), BlackRock, Inc. (84,924 shares), JONES FINANCIAL COMPANIES LLLP (53,500 shares), RENAISSANCE TECHNOLOGIES LLC (53,264 shares), NORTHERN TRUST CORP (44,944 shares), PRELUDE CAPITAL MANAGEMENT, LLC (35,820 shares), STATE STREET CORP (34,437 shares), and Sandhill Capital Partners LLC (15,400 shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.